SUN PHARMA ADVANCED RESEARCH COMPANY
|
SUN PHARMA ADVANCED RESEARCH COMPANY Last 5 Year Cashflow Statement History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|
| Profit Before Tax | ₹-343 Cr | ₹-387 Cr | ₹-223 Cr |
| Adjustment | ₹21 Cr | ₹-11 Cr | ₹6.99 Cr |
| Changes In working Capital | ₹-47 Cr | ₹-27 Cr | ₹141 Cr |
| Cash Flow after changes in Working Capital | ₹-369 Cr | ₹-425 Cr | ₹-74 Cr |
| Cash Flow from Operating Activities | ₹-360 Cr | ₹-429 Cr | ₹-69 Cr |
| Cash Flow from Investing Activities | ₹158 Cr | ₹392 Cr | ₹-548 Cr |
| Cash Flow from Financing Activities | ₹199 Cr | ₹42 Cr | ₹617 Cr |
| Net Cash Inflow / Outflow | ₹-3.38 Cr | ₹4.74 Cr | ₹-0.64 Cr |
| Opening Cash & Cash Equivalents | ₹5.33 Cr | ₹0.58 Cr | ₹1.22 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - |
| Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - |
| Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - |
| Effect of Foreign Exchange Fluctuations | ₹0.01 Cr | ₹0.00 Cr | - |
| Closing Cash & Cash Equivalent | ₹1.96 Cr | ₹5.33 Cr | ₹0.58 Cr |
Compare Cashflow Statement of peers of SUN PHARMA ADVANCED RESEARCH COMPANY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUN PHARMA ADVANCED RESEARCH COMPANY | ₹7,713.4 Cr | 3.7% | 29.6% | 45.9% | Stock Analytics | |
| SAGILITY | ₹18,561.5 Cr | -0.9% | -5.8% | 2.2% | Stock Analytics | |
| PRIME FOCUS | ₹17,890.5 Cr | -5% | -9.7% | 95.1% | Stock Analytics | |
| SYNGENE INTERNATIONAL | ₹17,797.8 Cr | -2.6% | -5.5% | -32.5% | Stock Analytics | |
| INTERNATIONAL GEMOLOGICAL INSTITUTE | ₹15,367.6 Cr | -3.7% | 1% | -7.9% | Stock Analytics | |
| INDEGENE | ₹12,829.2 Cr | 3.7% | 3.5% | -13.6% | Stock Analytics | |
SUN PHARMA ADVANCED RESEARCH COMPANY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMA ADVANCED RESEARCH COMPANY | 3.7% |
29.6% |
45.9% |
| SENSEX | 1.7% |
2.1% |
-6% |
You may also like the below Video Courses